Aqueous two-phase deposition and fibrinolysis of fibroblast-laden fibrin micro-scaffolds
Source abstract
Abstract
Abstract This paper describes printing of microscale fibroblast-laden matrices using an aqueous two-phase approach that controls thrombin-mediated enzymatic crosslinking of fibrin. Optimization of aqueous two-phase formulations enabled polymerization of consistent sub-microliter volumes of cell-laden fibrin. When plasminogen was added to these micro-scaffolds, the primary normal human lung fibroblasts converted it to plasmin, triggering gradual degradation of the fibrin. Time-lapse live-cell imaging and automated image analysis provided readouts of time to degradation of 50% of the scaffold as well as maximum degradation rate. The time required for degradation decreased linearly with cell number while it increased in a dose-dependent manner upon addition of TGF- β 1. Fibroblasts isolated from idiopathic pulmonary fibrosis patients showed similar trends with regards to response to TGF- β 1 stimulation. Addition of reactive oxygen species (ROS) slowed fibrinolysis but only in the absence of TGF- β 1, consistent with published studies demonstrating that pro-fibrotic cellular phenotypes induced by TGF- β 1 are mediated, at least in part, through increased production of ROS. FDA-approved and experimental anti-fibrosis drugs were also tested for their effects on fibrinolysis rates. Given the central role of fibrinolysis in both normal and pathogenic wound healing of various tissues, the high-throughput cell-mediated fibrinolysis assay described has broad applicability in the study of many different cell types and diseases. Furthermore, aqueous two-phase printing of fibrin addresses several current limitations of fibrin bio-inks, potentially enabling future applications in tissue engineering and in vitro models.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Periodontal Regeneration and Treatments · Wound Healing and Treatments · Electrospun Nanofibers in Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Fibrinogen and fibrin structure and functions10.1111/j.1538-7836.2005.01365.x ↗
2. Fibrin structure and wound healing10.1111/j.1538-7836.2006.01861.x ↗
3. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice10.1161/01.RES.0000141427.61023.f4 ↗
4. The role of plasminogen activator inhibitor type-1 in fibrosis10.1055/s-0036-1586228 ↗
5. Differential adhesion and fibrinolytic activity of mesenchymal stem cells from human bone marrow, placenta, and Wharton’s jelly cultured in a fibrin hydrogel10.1177/2041731419840622 ↗
6. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling10.1182/asheducation-2001.1.1 ↗
7. The role of fibrinolysis inhibition in engineered vascular networks derived from endothelial cells and adipose-derived stem cells10.1186/s13287-017-0764-2 ↗
8. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator10.1242/jcs.084392 ↗
9. Endothelial fibrinolytic response onto an evolving matrix of fibrin10.1186/s12878-016-0048-6 ↗
10. Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis10.4049/jimmunol.176.9.5607 ↗
11. Molecular mechanisms of fibrinolysis10.1111/j.1365-2141.2005.05444.x ↗
12. The plasmin system in airway remodeling10.1016/j.thromres.2003.10.011 ↗
13. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo10.1055/s-0038-1651570 ↗
14. Thrombin activatable fibrinolysis inhibitor (TAFI)–how does thrombin regulate fibrinolysis?10.1080/07853890600852898 ↗
15. Human cathepsins K, L, and S: related proteases, but unique fibrinolytic activity10.1016/j.bbagen.2018.06.015 ↗
16. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model10.1164/rccm.201312-2221PP ↗
17. Idiopathic pulmonary fibrosis10.1016/S0140-6736(11)60052-4 ↗
18. PAI-1, fibrosis, and the elusive provisional fibrin matrix10.1172/JCI11765 ↗
19. The plasminogen activation system in lung disease10.2174/138945007781662319 ↗
20. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system10.1016/S0002-9440(10)64529-4 ↗
21. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses10.1164/rccm.201403-0509PP ↗
22. The role of biophysical properties of provisional matrix proteins in wound repair10.1016/j.matbio.2016.08.004 ↗
23. The rate of fibrinolysis is increased by free retraction of human gingival fibroblast populated fibrin lattices10.1016/S1357-2725(96)00130-6 ↗
24. Evaluation of hydrogels for bio-printing applications10.1002/jbm.a.34326 ↗
25. Aqueous two-phase printing of cell-containing contractile collagen microgels10.1016/j.biomaterials.2013.08.046 ↗
26. Fibrin: a versatile scaffold for tissue engineering applications10.1089/ten.teb.2007.0435 ↗
27. Laser assisted bioprinting of engineered tissue with high cell density and microscale organization10.1016/j.biomaterials.2010.05.055 ↗
28. Viability and electrophysiology of neural cell structures generated by the inkjet printing method10.1016/j.biomaterials.2006.01.048 ↗
29. Fibrin gel as an injectable biodegradable scaffold and cell carrier for tissue engineering10.1155/2015/685690 ↗
30. Fibrin microbeads (FMB) as biodegradable carriers for culturing cells and for accelerating wound healing10.1046/j.1523-1747.1999.00600.x ↗
31. Driving forces for phase separation and partitioning in aqueous two-phase systems10.1016/S0378-4347(97)00585-9 ↗
32. Microplate coagulation assays
33. Global assays of fibrinolysis10.1111/ijlh.12688 ↗
34. Trypsin-induced proteome alteration during cell subculture in mammalian cells10.1186/1423-0127-17-36 ↗
35. Activation of plasminogen by trypsin and plasmin10.1182/blood.V7.9.882.882 ↗
36. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy10.1161/01.ATV.20.5.1354 ↗
37. TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities10.1016/j.cellsig.2012.10.003 ↗
38. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts10.1111/1523-1747.ep12338552 ↗
39. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach10.1074/jbc.M100754200 ↗
40. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts10.1002/jcp.1041650324 ↗
41. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression10.1055/s-0037-1613457 ↗
42. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a10.1016/S0092-8674(00)81902-9 ↗
43. Selective inhibition of collagen prolyl 4-hydroxylase in human cells10.1021/acschembio.5b00749 ↗
44. Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis10.1016/j.exger.2014.11.018 ↗
45. Lung fibroblasts, aging, and idiopathic pulmonary fibrosis10.1513/AnnalsATS.201605-341AW ↗
46. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions10.1111/j.1755-5922.2010.00171.x ↗
47. Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac110.1055/s-0037-1613480 ↗
48. Oxidative exposure impairs TGF-beta pathway via reduction of type II receptor and SMAD3 in human skin fibroblasts10.1007/s11357-014-9623-6 ↗
49. Transforming growth factor-beta promotes fibroblast apoptosis induced by H2O210.1080/01902140303773 ↗
50. Prolyl 4-hydroxylase10.3109/10409231003627991 ↗
51. A conserved family of prolyl-4-hydroxylases that modify HIF10.1126/science.1066373 ↗
52. Serpin regulation of fibrinolytic system: implications for therapeutic applications in cardiovascular diseases10.2174/1871525712666141106095927 ↗
53. Fibrinolysis: the key to new pathogenetic mechanisms10.2174/092986708783955455 ↗
54. Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and alpha2-antiplasmin inactivation10.1161/CIRCULATIONAHA.116.024421 ↗